Buchumschlag

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Selena Z. Kuo, Jeffrey Yin, Rohit Loomba
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial
von: Cynthia Levy, et al.
Veröffentlicht: (2026)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
von: Leyu Zhou, et al.
Veröffentlicht: (2024)

Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis
von: Huiying Lin, et al.
Veröffentlicht: (2025)

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis
von: Nadir Abbas, et al.
Veröffentlicht: (2025)

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
von: Jörn M. Schattenberg, et al.
Veröffentlicht: (2026)

Letter on ‘Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis’
von: Yi Pei, et al.
Veröffentlicht: (2025)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis
von: Ao Gao, et al.
Veröffentlicht: (2026)

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation
von: Ellen Werner, et al.
Veröffentlicht: (2026)

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
von: Luis Antonio Díaz, et al.
Veröffentlicht: (2025)

Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study
von: Kris V. Kowdley, et al.
Veröffentlicht: (2025)

Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
von: Mariko Maxwell, et al.
Veröffentlicht: (2026)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
von: Bo Li, et al.
Veröffentlicht: (2024)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
von: Federica Tavaglione, et al.
Veröffentlicht: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
von: Maral Amangurbanova, et al.
Veröffentlicht: (2024)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
von: Conrado Fernandez‐Rodriguez, et al.
Veröffentlicht: (2024)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
von: Luis Antonio Díaz, et al.
Veröffentlicht: (2025)

A Message From the Editors
von: Colin W. Howden, et al.
Veröffentlicht: (2024)

Dual Positivity for AMA / AMA ‐ M2 and Anti‐gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
von: Samer Gawrieh, et al.
Veröffentlicht: (2024)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
von: Maryam Zafer, et al.
Veröffentlicht: (2025)

Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia—Results of a Post Hoc Analysis of the Phase 3 PALISADE Study
von: Rohit Loomba, et al.
Veröffentlicht: (2026)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
von: Donghee Kim, et al.
Veröffentlicht: (2025)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
von: Donghee Kim, et al.
Veröffentlicht: (2025)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
von: Chia‐Chih Kuo, et al.
Veröffentlicht: (2025)

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
von: Matheus Souza, et al.
Veröffentlicht: (2026)

Editorial: Patient Reported Outcomes Provide Insight Into Disease Severity for People Living With Primary Sclerosing Cholangitis
von: Aisha Alawi, et al.
Veröffentlicht: (2025)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
von: Nikita Mittal, et al.
Veröffentlicht: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2025)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Research Communication: Real‐World Effectiveness of Budesonide Orodispersible Tablets for Eosinophilic Oesophagitis: The Importance of Patience and Education
von: Sarah Taylor, et al.
Veröffentlicht: (2025)

Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi‐Centre Propensity Score Matched Analysis
von: Saqr Alsakarneh, et al.
Veröffentlicht: (2025)

Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study
von: Harris Siddiqi, et al.
Veröffentlicht: (2024)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
von: Mazen Noureddin, et al.
Veröffentlicht: (2025)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
von: Takao Miwa, et al.
Veröffentlicht: (2026)

Research Communication: Healthcare Utilisation Patterns in Patients With Irritable Bowel Syndrome Across an Integrated Healthcare System
von: Neil S. Zheng, et al.
Veröffentlicht: (2025)

Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures
von: Raj Vuppalanchi, et al.
Veröffentlicht: (2024)